Comparison of Framingham risk score and Globorisk among Type 2 Diabetes subjects with and without CVD

Objective: Cardiovascular risk prediction models are very effective way to assess the 10 years cardiovascular disease risk prediction among the populations. The present study determined the validity and utility of two important risk prediction models Framingham Risk Score (FRS) and Globorisk among Type 2 Diabetes (T2DM) subjects with cardiovascular disease (CVD) and without CVD. Methods: Consecutively 208 subjects with T2DM were recruited and they were categorized into 2 groups: Group 1 consisted of 103 patients with CVD and Group 2 consisted of 105 patients without CVD. 10-years CVD risk estimations for both groups were assessed using two risk calculators. FRS and Globorisk. Risk equation, Sensitivity and Specificity were examined by comparing areas under the receiver operating characteristic (ROC) curve to evaluate the discriminative ability of competing risk model. Results: Out of 208 study subjects analyzed for CVD risk by 2 models. FRS CVD risk assessment was better compared with globorisk, where FRS showed nearly 56.3% of high risk individuals with a statistically significance (p=<0.0001) when compared between CVD and Non-CVD subjects. Conclusion: Framingham risk score showed better performance than globorisk score. FRS model can be better tool than globorisk in predicting the high cardiovascular risk subjects with T2DM.